ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One ...
A single lot of apixaban 5-mg tablets is being recalled nationwide following a customer complaint about the wrong dosage, the manufacturer has announced. The US Food and Drug Administration (FDA) ...
Only anticoagulant proven to show superior risk reductions versus warfarin in three important outcomes: stroke, major bleeding and all-cause death First approval in any market worldwide of ELIQUIS for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback